Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 6/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22023906 | 0.94 | ESR1 (0.42) | ESR1ACLYHDAC3HDAC1HDAC11 | |
| SCHEMBL22246056 | 0.93 | ESR1 (0.41) | ESR1HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL3214672 | 0.93 | ESR1 (0.41) | ESR1HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL15005386 | 0.93 | ESR1 (0.41) | ESR1HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL11819809 | 0.93 | ESR1 (0.41) | ESR1HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL18949950 | 0.88 | ESR1 (0.49) | ESR1ESR2ACLYHDAC3CHRM3 | |
| SCHEMBL22023927 | 0.85 | ESR1 (0.43) | ESR1ESR2HDAC3HDAC1HDAC11 | |
| SCHEMBL21507866 | 0.81 | ESR1 (0.41) | ESR1ESR2HDAC3HDAC1HDAC11 | |
| SCHEMBL158645 | 0.81 | ESR1 (0.44) | ESR1ESR2HDAC3HDAC1HDAC11 | |
| SCHEMBL18387967 | 0.81 | ESR1 (0.41) | ESR1ESR2ACLYHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041563-A1 | N-(1,3,4-OXADIAZOL-2-YL)ARYLCARBOXAMIDES OR SALTS THEREOF, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND USES THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20220204452-A1 | ANTIMALARIAL COMPOUNDS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2022-06-30 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11008339-B2 | Substituted pyrazole compounds containing pyrimidine and preparation method and use thereof | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2021-05-18 | — | — | US | disclosed |
| US-10934270-B2 | Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity | NORTHWESTERN UNIVERSITY (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200071292-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2020-03-05 | — | — | US | disclosed |
| US-20190322617-A1 | HDAC8 INHIBITORS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-24 | — | — | US | disclosed |
| US-10167270-B2 | Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity | NORTHWESTERN UNIVERSITY (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180141961-A1 | Substituted Pyrazole Compounds Containing Pyrimidine and Preparation Method and Use Thereof | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2018-05-24 | — | — | US | disclosed |
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-04-19 | — | — | US | disclosed |
| US-6492397-B1 | SUCH AS 1-PROPYL-4-BUTYL-1,3-DIHYDRO-3-((5-(2-(1H-TETRAZOL-5-YL)PHENYL)-2 -PYRIDINYL)METHYL)-2H-IMIDAZOL-2-ONE; ANGIO-TENSIN II ANTAGONISTS; CIRCULATORY DISORDERS; HYPERTENSION, CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934270-B2 | Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity | GBA1, GAA, GBA2 | ESR1 4877/4885ESR2 4731/4885ACLY 977/4885 |
| US-20230041563-A1 | N-(1,3,4-OXADIAZOL-2-YL)ARYLCARBOXAMIDES OR SALTS THEREOF, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND USES THEREOF | CYP2B6, CBR3, CYP2A6 | ESR1 1830/4885ESR2 1827/4885ACLY 437/4885 |
| US-20180141961-A1 | Substituted Pyrazole Compounds Containing Pyrimidine and Preparation Method and Use Thereof | APRT, GART, PNP | ESR1 4883/4885ESR2 4829/4885ACLY 25/4885 |
| US-20200071292-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | GBA1, GAA, GBA2 | ESR1 4877/4885ESR2 4731/4885ACLY 977/4885 |
| US-20190322617-A1 | HDAC8 INHIBITORS FOR TREATING CANCER | HDAC8, HDAC1, HDAC7 | ESR1 2652/4885ESR2 2572/4885ACLY 2025/4885 |
| US-11008339-B2 | Substituted pyrazole compounds containing pyrimidine and preparation method and use thereof | APRT, GART, PNP | ESR1 4883/4885ESR2 4829/4885ACLY 25/4885 |
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | ESR1 2485/4885ESR2 2921/4885ACLY 3220/4885 |
| US-10167270-B2 | Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity | GBA1, GAA, GBA2 | ESR1 4877/4885ESR2 4731/4885ACLY 977/4885 |
| US-20220204452-A1 | ANTIMALARIAL COMPOUNDS | H1-3, FPR3, NHERF1 | ESR1 4513/4885ESR2 4337/4885ACLY 1830/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | ESR1 1662/4885ESR2 2553/4885ACLY 2221/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | ESR1 1662/4885ESR2 2553/4885ACLY 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.